Charles E. Geyer, MD, FACP

Research outputs

  1. 2020
  2. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2

    Fehrenbacher, L., Cecchini, R. S., Geyer, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J. F., Provencher, L., Stokoe, C., Moore, T. D., Robidoux, A., Flynn, P. J., Borges, V. F., Albain, K. S., Swain, S. M., Paik, S., Mamounas, E. P. & Wolmark, N., Feb 10 2020, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38, 5, p. 444-453 10 p.

    Research output: Contribution to journalArticle

  3. 2019
  4. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination

    Swain, S. M., Tang, G., Lucas, P. C., Robidoux, A., Goerlitz, D., Harris, B. T., Bandos, H., Geyer, C. E., Rastogi, P., Mamounas, E. P. & Wolmark, N., Nov 1 2019, In : Breast Cancer Research and Treatment. 178, 2, p. 389-399 11 p.

    Research output: Contribution to journalArticle

  5. Nab-paclitaxel: A new standard of care in neoadjuvant therapy of high-risk early breast cancer?

    Ross, M. & Geyer, C., Sep 1 2019, In : Journal of Clinical Oncology. 37, 25, p. 2196-2200 5 p.

    Research output: Contribution to journalReview article

  6. Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

    Kim, R. S., Song, N., Gavin, P. G., Salgado, R., Bandos, H., Kos, Z., Floris, G., Eynden, G. G. G. M. V. D., Badve, S., Demaria, S., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., Swain, S. M., Wickerham, D. L., Costantino, J. P., Paik, S., Wolmark, N., Geyer, C., Lucas, P. C. & 1 othersPogue-Geile, K. L., Aug 1 2019, In : Journal of the National Cancer Institute. 111, 8, p. 867-871 5 p.

    Research output: Contribution to journalArticle

  7. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer

    Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Keane, M. M. & 10 othersGomez Moreno, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Brufsky, A. M., Toppmeyer, D. L., Kaklamani, V. G., Berenberg, J. L., Abrams, J. & Sledge, G. W., Jun 20 2019, In : New England Journal of Medicine. 380, 25, p. 2395-2405 11 p.

    Research output: Contribution to journalArticle

  8. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Apr 6 2019, In : The Lancet. 393, 10179, p. 1440-1452 13 p.

    Research output: Contribution to journalArticle

  9. Trastuzumab emtansine for residual invasive HER2-positive breast cancer

    Von Minckwitz, G., Huang, C. S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., Fischer, H. H., Jacot, W., Conlin, A. K., Arce-Salinas, C., Wapnir, I. L., Jackisch, C., DiGiovanna, M. P., Fasching, P. A., Crown, J. P., Wülfing, P. & 9 othersShao, Z., Caremoli, E. R., Wu, H., Lam, L. H., Tesarowski, D., Smitt, M., Douthwaite, H., Singel, S. M. & Geyer, C. E., Feb 14 2019, In : New England Journal of Medicine. 380, 7, p. 617-628 12 p.

    Research output: Contribution to journalArticle

  10. Breast Conservation after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results from the BrighTNess Randomized Clinical Trial

    Golshan, M., Loibl, S., Wong, S. M., Houber, J. B., O'Shaughnessy, J., Rugo, H. S., Wolmark, N., McKee, M. D., Maag, D., Sullivan, D. M., Metzger-Filho, O., Von Minckwitz, G., Geyer, C. E., Sikov, W. M. & Untch, M., Jan 1 2019, In : JAMA Surgery.

    Research output: Contribution to journalArticle

  11. Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

    Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D. L., Brufsky, A. M., Goetz, M. P., Berenberg, J. L., Mahalcioiu, C., Desbiens, C., Hayes, D. F. & 9 othersDees, E. C., Geyer, C., Olson, J. A., Wood, W. C., Lively, T., Paik, S., Ellis, M. J., Abrams, J. & Sledge, G. W., Jan 1 2019, In : JAMA oncology.

    Research output: Contribution to journalArticle

  12. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial

    Golshan, M., Wong, S. M., Loibl, S., Huober, J. B., O'Shaughnessy, J., Rugo, H. S., Wolmark, N., Ansell, P., Maag, D., Sullivan, D. M., Metzger-Filho, O., Von Minckwitz, G., Geyer, C. E., Sikov, W. M. & Untch, M., Jan 1 2019, In : European Journal of Surgical Oncology.

    Research output: Contribution to journalArticle

  13. OpenNotes in oncology: Oncologists’ perceptions and a baseline of the content and style of their clinician notes

    Alpert, J. M., Morris, B. B., Thomson, M. D., Matin, K., Geyer, C. & Brown, R. F., Jan 1 2019, In : Translational Behavioral Medicine. 9, 2, p. 347-356 10 p.

    Research output: Contribution to journalArticle

  14. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

    Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Rastogi, P., Fehrenbacher, L., Graham, M. L., Chia, S. K., Brufsky, A. M., Walshe, J. M., Soori, G. S., Dakhil, S. R., Seay, T. E., Wade, J. L., McCarron, E. C., Paik, S., Swain, S. M., Wickerham, D. L. & Wolmark, N., Jan 1 2019, In : The Lancet Oncology. 20, 1, p. 88-99 12 p.

    Research output: Contribution to journalArticle

  15. 2018
  16. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

    Geyer, C., Tang, G., Mamounas, E. P., Rastogi, P., Paik, S., Shak, S., Baehner, F. L., Crager, M., Wickerham, D. L., Costantino, J. P. & Wolmark, N., Dec 1 2018, In : npj Breast Cancer. 4, 1, 37.

    Research output: Contribution to journalArticle

  17. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer

    Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P. M., Keane, M. M. & 10 othersGomez Moreno, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Brufsky, A. M., Toppmeyer, D. L., Kaklamani, V. G., Berenberg, J. L., Abrams, J. & Sledge, G. W., Jul 12 2018, In : New England Journal of Medicine. 379, 2, p. 111-121 11 p.

    Research output: Contribution to journalArticle

  18. Tailoring adjuvant endocrine therapy for premenopausal breast cancer

    Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., Bonnefoi, H. R., Bellet, M., Martino, S., Geyer, C. E., Goetz, M. P., Stearns, V., Pinotti, G., Puglisi, F., Spazzapan, S., Climent, M. A. & 16 othersPavesi, L., Ruhstaller, T., Davidson, N. E., Coleman, R., Debled, M., Buchholz, S., Ingle, J. N., Winer, E. P., Maibach, R., Rabaglio-Poretti, M., Ruepp, B., Di Leo, A., Coates, A. S., Gelber, R. D., Goldhirsch, A. & Regan, M. M., Jul 12 2018, In : New England Journal of Medicine. 379, 2, p. 122-137 16 p.

    Research output: Contribution to journalArticle

  19. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial

    Wapnir, I. L., Price, K. N., Anderson, S. J., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Láng, I., Baena-Cañada, J. M., Thürlimann, B., Mamounas, E. P., Geyer, C. E., Gelber, S., Coates, A. S., Gelber, R. D., Rastogi, P., Regan, M. M., Wolmark, N. & Aebi, S., Apr 10 2018, In : Journal of Clinical Oncology. 36, 11, p. 1073-1079 7 p.

    Research output: Contribution to journalArticle

  20. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., Sullivan, D., Wolmark, N., McIntyre, K., Ponce Lorenzo, J. J., Metzger Filho, O., Rastogi, P., Symmans, W. F., Liu, X. & Geyer, C., Apr 1 2018, In : The Lancet Oncology. 19, 4, p. 497-509 13 p.

    Research output: Contribution to journalArticle

  21. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014

    Schroeder, M. C., Rastogi, P., Geyer, C., Miller, L. D. & Thomas, A., Apr 1 2018, In : Oncologist. 23, 4, p. 481-488 8 p.

    Research output: Contribution to journalArticle

  22. Clinical trials in older, less fit populations: an unmet need?

    Geyer, C. E., Mar 1 2018, In : The Lancet Oncology. 19, 3, p. 271-272 2 p.

    Research output: Contribution to journalComment/debate

  23. 2017
  24. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: A randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with ac followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2

    Ganz, P. A., Romond, E. H., Cecchini, R. S., Rastogi, P., Geyer, C. E., Swain, S. M., Jeong, J. H., Fehrenbacher, L., Gross, H. M., Brufsky, A. M., Flynn, P. J., Wahl, T. A., Seay, T. E., Wade, J. L., Biggs, D. D., Atkins, J. N., Polikoff, J., Zapas, J. L., Mamounas, E. P. & Wolmark, N., Dec 10 2017, In : Journal of Clinical Oncology. 35, 35, p. 3942-3948 7 p.

    Research output: Contribution to journalArticle

  25. Diagnosis and management of breast tumors: A practical handbook and multidisciplinary approach

    Idowu, M. O., Shah, P. A., Hackney, M. H., Grimes, M. M., Geyer, C., Arthur, D. W. & Bear, H. D., Sep 25 2017, Springer International Publishing. 255 p.

    Research output: Book/ReportBook

  26. Anthracyclines in early breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)

    Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C., Jacobs, S. A., Robert, N. J., Hopkins, J. O., O’Shaughnessy, J. A., Dang, C. T., Gómez, H. L., Fehrenbacher, L., Vukelja, S. J., Lyss, A. P., Paul, D., Brufsky, A. M., Jeong, J. H., Colangelo, L. H., Swain, S. M., Mamounas, E. P. & 2 othersJones, S. E. & Wolmark, N., Aug 10 2017, In : Journal of Clinical Oncology. 35, 23, p. 2647-2655 9 p.

    Research output: Contribution to journalArticle

  27. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

    Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Zoon, C. K., Kidwell, K. M., Robidoux, A., Baez-Diaz, L., Brufsky, A. M., Mehta, R. S., Fehrenbacher, L., Young, J. A., Senecal, F. M., Gaur, R., Margolese, R. G., Adams, P. T., Gross, H. M., Costantino, J. P., Paik, S., Swain, S. M. & 2 othersMamounas, E. P. & Wolmark, N., Jul 1 2017, In : Annals of Surgical Oncology. 24, 7, p. 1853-1860 8 p.

    Research output: Contribution to journalArticle

  28. Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2-positive breast cancer analysis of the NSABP B-31 trial

    Gavin, P. G., Song, N., Rim Kim, S., Lipchik, C., Johnson, N. L., Bandos, H., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., Swain, S. M., Lawrence Wickerham, D., Geyer, C., Jeong, J. H., Costantino, J. P., Wolmark, N., Paik, S. & Pogue-Geile, K. L., Mar 1 2017, In : JAMA oncology. 3, 3, p. 335-341 7 p.

    Research output: Contribution to journalArticle

  29. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5

    Smith, J. W., Buyse, M. E., Rastogi, P., Geyer, C., Jacobs, S. A., Patocskai, E. J., Robidoux, A., Conlin, A. K., Ansari, B., Keogh, G. P., Stella, P. J., Gross, H. M., Lord, R. S., Polikoff, J. A., Mauquoi, C., Mamounas, E. P., Swain, S. M. & Wolmark, N., Feb 1 2017, In : Clinical Breast Cancer. 17, 1, p. 48-54.e3

    Research output: Contribution to journalArticle

  30. Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

    On behalf of CALOR trial investigators, Feb 1 2017, In : Annals of Surgical Oncology. 24, 2, p. 398-406 9 p.

    Research output: Contribution to journalArticle

  31. Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP)

    Rastogi, P., Wickerham, D. L., Geyer, C. E., Mamounas, E. P., Julian, T. B. & Wolmark, N., Jan 1 2017, In : Chinese Clinical Oncology. 6, 1, 7.

    Research output: Contribution to journalReview article

  32. 2016
  33. Phase I study of pemetrexed with sorafenib in advanced solid tumors

    Poklepovic, A., Gordon, S., Shafer, D. A., Roberts, J. D., Bose, P., Geyer, C. E., McGuire, W. P., Tombes, M. B., Shrader, E., Strickler, K., Quigley, M., Wan, W., Kmieciak, M., Massey, H. D., Booth, L., Moran, R. G. & Dent, P., Jul 5 2016, In : Oncotarget. 7, 27, p. 42625-42638 14 p.

    Research output: Contribution to journalArticle

  34. Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer

    Lee, C. K., Davies, L., Gebski, V. J., Lord, S. J., Di Leo, A., Johnston, S., Geyer, C. E., Cameron, D., Press, M. F., Ellis, C., Loi, S., Marschner, I., Simes, J. & De Souza, P., Mar 20 2016, In : Journal of Clinical Oncology. 34, 9, p. 936-944 9 p.

    Research output: Contribution to journalArticle

  35. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38

    Cecchini, R. S., Swain, S. M., Costantino, J. P., Rastogi, P., Jeong, J. H., Anderson, S. J., Tang, G., Geyer, C. E., Lembersky, B. C., Romond, E. H., Paterson, A. H. G. & Wolmark, N., Jan 1 2016, In : Cancer Epidemiology Biomarkers and Prevention. 25, 1, p. 51-59 9 p.

    Research output: Contribution to journalArticle

  36. Professor Charles E. Geyer: Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer

    Geyer, C. E., Jan 1 2016, In : Chinese Clinical Oncology. 5, 5

    Research output: Contribution to journalEditorial

  37. 2015
  38. Prospective validation of a 21-gene expression assay in breast cancer

    Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C., Dees, E. C., Perez, E. A., Olson, J. A., Zujewski, J. A., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P. & 11 othersKeane, M. M., Gomez Moreno, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Brufsky, A. M., Toppmeyer, D. L., Kaklamani, V. G., Atkins, J. N., Berenberg, J. L. & Sledge, G. W., Nov 19 2015, In : New England Journal of Medicine. 373, 21, p. 2005-2014 10 p.

    Research output: Contribution to journalArticle

  39. Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Oct 3 2015, In : The Lancet. 386, 10001, p. 1353-1361 9 p.

    Research output: Contribution to journalArticle

  40. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials

    Early Breast Cancer Trialists’ Collaborative Group, Oct 3 2015, In : The Lancet. 386, 10001, p. 1341-1352 12 p.

    Research output: Contribution to journalArticle

  41. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial

    Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Liu, Q., Robidoux, A., Baez-Diaz, L., Brufsky, A. M., Mehta, R. S., Fehrenbacher, L., Young, J. A., Senecal, F. M., Gaur, R., Margolese, R. G., Adams, P. T., Gross, H. M., Costantino, J. P., Paik, S., Swain, S. M., Mamounas, E. P. & 1 othersWolmark, N., Sep 1 2015, In : The Lancet Oncology. 16, 9, p. 1037-1048 12 p., 44.

    Research output: Contribution to journalArticle

  42. Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer

    Cortazar, P. & Geyer, C. E., May 1 2015, In : Annals of Surgical Oncology. 22, 5, p. 1441-1446 6 p.

    Research output: Contribution to journalArticle

  43. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

    Pogue-Geile, K. L., Song, N., Jeong, J. H., Gavin, P. G., Kim, S. R., Blackmon, N. L., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., Swain, S. M., Wickerham, D. L., Geyer, C., Costantino, J. P., Wolmark, N. & Paik, S., Apr 20 2015, In : Journal of Clinical Oncology. 33, 12, p. 1340-1347 8 p.

    Research output: Contribution to journalArticle

  44. Adjuvant ovarian suppression in premenopausal breast cancer

    Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., Martino, S., Davidson, N. E., Geyer, C., Walley, B. A., Coleman, R., Kerbrat, P., Buchholz, S., Ingle, J. N., Winer, E. P. M., Rabaglio-Poretti, M. & 9 othersMaibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Colleoni, M., Viale, G., Coates, A. S., Goldhirsch, A. & Gelber, R. D., Jan 1 2015, In : New England Journal of Medicine. 372, 5, p. 436-446 11 p.

    Research output: Contribution to journalArticle

  45. Pathological complete response in breast cancer - Authors' reply

    Cortazar, P., Geyer, C., Gianni, L., Cameron, D. & Von Minckwitz, G., Jan 1 2015, In : The Lancet. 385, 9963, p. 114-115 2 p.

    Research output: Contribution to journalLetter

  46. Systemic therapy of locoregional recurrence of breast cancer

    Geyer, C., Jan 1 2015, In : Breast Diseases. 26, 2, p. 113-117 5 p.

    Research output: Contribution to journalArticle

  47. Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

    Tan, A. R., Johannes, H., Rastogi, P., Jacobs, S. A., Robidoux, A., Flynn, P. J., Thirlwell, M. P., Fehrenbacher, L., Stella, P. J., Goel, R., Julian, T. B., Provencher, L., Bury, M. J., Bhatt, K., Geyer, C., Swain, S. M., Mamounas, E. P. & Wolmark, N., Jan 1 2015, In : Breast Cancer Research and Treatment. 149, 1, p. 163-169 7 p.

    Research output: Contribution to journalArticle

  48. 2014
  49. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 - Positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831

    Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., Winer, E. P., Colon-Otero, G., Davidson, N. E., Mamounas, E., Zujewski, J. A. & Wolmark, N., Nov 20 2014, In : Journal of Clinical Oncology. 32, 33, p. 3744-3752 9 p.

    Research output: Contribution to journalArticle

  50. Reply to E.J. Moylan et al

    Swain, S. M., Tang, G. & Geyer, C. E., Feb 20 2014, In : Journal of Clinical Oncology. 32, 6, p. 606-607 2 p.

    Research output: Contribution to journalLetter

  51. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial

    Aebi, S., Gelber, S., Anderson, S. J., Láng, I., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Cañada, J. M. B., Thürlimann, B., Murray, E., Mamounas, E. P., Geyer, C. E., Price, K. N., Coates, A. S., Gelber, R. D., Rastogi, P., Wolmark, N. & Wapnir, I. L., Feb 1 2014, In : The Lancet Oncology. 15, 2, p. 156-163 8 p.

    Research output: Contribution to journalArticle

  52. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

    Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., Ciruelos, E., Stearns, V., Bonnefoi, H. R., Martino, S., Geyer, C. E., Pinotti, G., Puglisi, F., Crivellari, D., Ruhstaller, T., Winer, E. P. & 13 othersRabaglio-Poretti, M., Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Bernhard, J., Luo, W., Ribi, K., Viale, G., Coates, A. S., Gelber, R. D., Goldhirsch, A. & Francis, P. A., Jan 1 2014, In : New England Journal of Medicine. 371, 2, p. 107-118 12 p.

    Research output: Contribution to journalArticle

  53. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials

    McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., Gray, R., Mannu, G., Peto, R., Whelan, T., Wang, Y., Wang, Z., Darby, S., Albain, K., Anderson, S., Arriagada, R., Barlow, W., Bergh, J., Bergsten Nordström, E., Bliss, J. & 71 othersBurrett, J. A., Buyse, M., Cameron, D., Carrasco, E., Clarke, M., Coleman, R., Correa, C., Coates, A., Collins, R., Costantino, J., Cutter, D., Cuzick, J., Darby, S., Davidson, N., Davies, C., Davies, K., Delmestri, A., Di Leo, A., Dowsett, M., Elphinstone, P., Evans, V., Ewertz, M., Forbes, J., Gelber, R., Gettins, L., Geyer, C. E., Gianni, L., Gnant, M., Goldhirsch, A., Godwin, J., Gray, R., Gregory, C., Hayes, D., Hill, C., Ingle, J., Jakesz, R., James, S., Janni, W., Kaufmann, M., Kerr, A., Liu, H., MacKinnon, E., Martín, M., McGale, P., McHugh, T., Morris, P., Norton, L., Ohashi, Y., Paik, S., Pan, H. C., Perez, E., Piccart, M., Pierce, L., Pritchard, K., Pruneri, G., Raina, V., Ravdin, P., Robertson, J., Rutgers, E., Shao, Y. F., Sparano, J., Swain, S., Taylor, C., Valagussa, P., Viale, G., Von Minckwitz, G., Whelan, T., Winer, E., Wiang, X., Wang, Y. & Wood, W., Jan 1 2014, In : The Lancet. 383, 9935, p. 2127-2135 9 p.

    Research output: Contribution to journalArticle

  54. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis

    Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., Swain, S. M., Prowell, T., Loibl, S., Wickerham, D. L., Bogaerts, J., Baselga, J., Perou, C., Blumenthal, G., Blohmer, J., Mamounas, E. P. & 17 othersBergh, J., Semiglazov, V., Justice, R., Eidtmann, H., Paik, S., Piccart, M., Sridhara, R., Fasching, P. A., Slaets, L., Tang, S., Gerber, B., Geyer, C. E., Pazdur, R., Ditsch, N., Rastogi, P., Eiermann, W. & Von Minckwitz, G., Jan 1 2014, In : The Lancet. 384, 9938, p. 164-172 9 p.

    Research output: Contribution to journalArticle

  55. 2013
  56. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31

    Pogue-Geile, K. L., Kim, C., Jeong, J. H., Tanaka, N., Bandos, H., Gavin, P. G., Fumagalli, D., Goldstein, L. C., Sneige, N., Burandt, E., Taniyama, Y., Bohn, O. L., Lee, A., Kim, S. I., Reilly, M. L., Remillard, M. Y., Blackmon, N. L., Kim, S. R., Horne, Z. D., Rastogi, P. & 9 othersFehrenbacher, L., Romond, E. H., Swain, S. M., Mamounas, E. P., Wickerham, D. L., Geyer, C. E., Costantino, J. P., Wolmark, N. & Paik, S., Dec 4 2013, In : Journal of the National Cancer Institute. 105, 23, p. 1782-1788 7 p.

    Research output: Contribution to journalArticle

  57. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

    Martin, M., Bonneterre, J., Geyer, C. E., Ito, Y., Ro, J., Lang, I., Kim, S. B., Germa, C., Vermette, J., Wang, K., Wang, K. & Awada, A., Dec 1 2013, In : European Journal of Cancer. 49, 18, p. 3763-3772 10 p.

    Research output: Contribution to journalArticle

  58. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial

    Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., Fehrenbacher, L., Bear, H. D., Baez-Diaz, L., Sarwar, S., Margolese, R. G., Farrar, W. B., Brufsky, A. M., Shibata, H. R., Bandos, H., Paik, S., Costantino, J. P., Swain, S. M., Mamounas, E. P. & Wolmark, N., Nov 1 2013, In : The Lancet Oncology. 14, 12, p. 1183-1192 10 p.

    Research output: Contribution to journalArticle

Previous 1 2 3 Next

ID: 55736555